Skip to main content
Terug
Watch Compare

REGENXBIO Inc.

Datakwaliteit: 100%
RGNX
Nasdaq Manufacturing Chemicals
€ 8,80
▼ € 0,16 (-1,79%)
Marktkapitalisatie: 459,61 M
Prijs
€ 8,91
Marktkapitalisatie
459,61 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue declined -22,41% annually over 5 years
Negative free cash flow of -126,38 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 126,95%
Capital efficient — spends only 1,42% of revenue on capex

Groei

Revenue Growth (5Y)
-22,41%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)104,54%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-103,37%
Onder sectorgemiddelde (-53,47%)
ROIC-29,54%
Net Margin-113,75%
Op. Margin-94,58%

Veiligheid

Debt / Equity
N/A
Current Ratio2,66
Interest Coverage-3,58

Waardering

PE (TTM)
-2,37
Onder sectorgemiddelde (-1,48)
P/B Ratio2,85
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -2,4 -1,5
P/B 2,9 1,6
ROE % -103,4 -53,5
Net Margin % -113,8 -41,5
Rev Growth 5Y % -22,4 1,8
D/E — 0,3

Koersdoel Analisten

11 analisten
Buy
Huidig
€ 8,80
+216.1%
Koersdoel
€ 27,82
€ 12,00
€ 27,00
€ 50,00
Vooruitzicht
Forward K/W -4,01
Forward WPA -€ 2,20
Omzet Sch. 305,95 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 2,20
-€ 4,91 – € 0,61
 305,95 M 5
FY2026 -€ 2,00
-€ 4,87 – € 1,61
 255,53 M 8

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,84 -€ 1,30 -54,9%
Q32025 -€ 1,30 -€ 1,20 +7,6%
Q22025 -€ 1,05 -€ 1,38 -30,8%
Q12025 € 0,49 € 0,12 -75,3%

ETFs Holding This Stock

WDNA WDNA
1,81% weight
BBC logo BBC Virtus Biotech Clinical Trials ETF
0,67% weight
DLHAX DLHAX
0,31% weight
DLRHX DLRHX
0,31% weight
DLHIX DLHIX
0,31% weight
BDSAX BDSAX
0,13% weight
BDSCX BDSCX
0,13% weight
BDSIX BDSIX
0,13% weight
BDSKX BDSKX
0,13% weight
PSGIX PSGIX
0,10% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 104,54% Revenue Growth (3Y) 37,43%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -22,41% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 170,44 M Net Income (TTM) -193,88 M
ROE -103,37% ROA -35,05%
Gross Margin N/A Operating Margin -94,58%
Net Margin -113,75% Free Cash Flow (TTM) -126,38 M
ROIC -29,54% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2,66
Interest Coverage -3,58 Asset Turnover 0,31
Working Capital 207,40 M Tangible Book Value 161,45 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2,37 Forward P/E N/A
P/B Ratio 2,85 P/S Ratio 2,70
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -27,50%
Market Cap 459,61 M Enterprise Value 400,81 M
Per Share
EPS (Diluted TTM) -3,76 Revenue / Share 3,30
FCF / Share -2,45 OCF / Share -2,40
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 1,42% FCF Conversion 65,18%
SBC-Adj. FCF -162,45 M Growth Momentum 126,95

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 170,44 M 83,33 M 90,24 M 112,72 M 470,35 M
Net Income -193,88 M -227,10 M -263,49 M -280,32 M 127,84 M
EPS (Diluted) -3,76 -4,59 -6,02 -6,50 2,91
Gross Profit — — — — —
Operating Income -161,20 M -233,35 M -268,13 M -262,88 M 159,98 M
EBITDA — — — — —
R&D Expenses 228,30 M 208,52 M 232,27 M 242,45 M 181,44 M
SG&A Expenses — — — — —
D&A 15,62 M 16,22 M 17,32 M 12,91 M 9,56 M
Interest Expense 45,01 M 12,66 M 6,86 M 23,25 M 26,28 M
Income Tax 0,0 -152.000,0 -152.000,0 -84.000,0 13,41 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 453,03 M 465,99 M 573,97 M 833,27 M 1,11 B
Total Liabilities 350,30 M 206,34 M 262,23 M 317,07 M 349,61 M
Shareholders' Equity 102,73 M 259,65 M 311,74 M 516,20 M 764,30 M
Total Debt — — — — —
Cash & Equivalents 34,47 M 57,53 M 34,52 M 96,95 M 345,21 M
Current Assets 281,28 M 278,00 M 334,97 M 415,98 M 518,83 M
Current Liabilities 118,10 M 103,19 M 130,27 M 130,43 M 130,47 M